Search research articles
Contact Us
Filters
Showing results (51-60 of 122) with videos related to
Page
of 13
Sort By:
American Journal of Hematology
|
August 12, 2020
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies
Marzia Varettoni, Angela Ferrari, Anna M Frustaci, et al.
Hematological Oncology
|
May 18, 2017
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study
Francesca Palandri, Mario Tiribelli, Giulia Benevolo, et al.
Blood
|
September 29, 2011
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment
Fortunato Morabito, Massimo Gentile, Carla Mazzone, et al.
Blood
|
September 3, 2010
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
Sara Bringhen, Alessandra Larocca, Davide Rossi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 30, 2021
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients
Gian Maria Zaccaria, Luca Bertamini, Maria Teresa Petrucci, et al.
British Journal of Haematology
|
November 28, 2024
Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trial
Giulia Benevolo, Daniela Drandi, Nicoletta Villivà, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 19, 2018
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response
Roberto Mina, Maria Teresa Petrucci, Paolo Corradini, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 25, 2025
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis
Francesca Palandri, Massimo Breccia, Erika Morsia, et al.
Blood Cancer Journal
|
April 13, 2021
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score
Mattia D'Agostino, Alessandra Larocca, Massimo Offidani, et al.
Blood
|
January 6, 2016
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma
Valeria Magarotto, Sara Bringhen, Massimo Offidani, et al.
Page
of 13
Search research articles
Search
Showing results (51-60 of 122) with videos related to
Sort By:
Page
of 13
American Journal of Hematology
|
August 12, 2020
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies
Marzia Varettoni, Angela Ferrari, Anna M Frustaci, et al.
Hematological Oncology
|
May 18, 2017
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study
Francesca Palandri, Mario Tiribelli, Giulia Benevolo, et al.
Blood
|
September 29, 2011
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment
Fortunato Morabito, Massimo Gentile, Carla Mazzone, et al.
Blood
|
September 3, 2010
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
Sara Bringhen, Alessandra Larocca, Davide Rossi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 30, 2021
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients
Gian Maria Zaccaria, Luca Bertamini, Maria Teresa Petrucci, et al.
British Journal of Haematology
|
November 28, 2024
Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trial
Giulia Benevolo, Daniela Drandi, Nicoletta Villivà, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 19, 2018
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response
Roberto Mina, Maria Teresa Petrucci, Paolo Corradini, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 25, 2025
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis
Francesca Palandri, Massimo Breccia, Erika Morsia, et al.
Blood Cancer Journal
|
April 13, 2021
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score
Mattia D'Agostino, Alessandra Larocca, Massimo Offidani, et al.
Blood
|
January 6, 2016
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma
Valeria Magarotto, Sara Bringhen, Massimo Offidani, et al.
Page
of 13